Advanced searches left 3/3

Treatment of Cancer - Springer Nature

Summarized by Plex Scholar
Last Updated: 18 April 2022

* If you want to update the article please login/register

A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naïve or opioid-resistant patients

Purpose This research sought to find out the clinical effectiveness of tapentadol extended-release on pain management and the quality of life of patients with moderate to severe chronic cancer pain in clinical practice in Korea. The mean pain intensity including neuropathic pain reduced by 2. 9 percentage points during the observation period. Conclusion This research showed that tapentadol ER was safe for treating patients with moderate to severe cancer pain and neuropathic pain, and hence, it greatly enhanced the patients' QoL.

Source link: https://doi.org/10.1007/s00520-022-06992-w


Lycopene as a Multifunctional Platform for the Treatment of Cancer and Inflammation

In the last few years, the use of oy lycopene as a nutraceutical has increased in the last two years, particularly due to its anti-inflammatory and anti-tumor properties. The main mechanisms involved in both anti-inflammatory and antitumor properties of lycopene are reviewed in this study, with the aim of determining its use as an anticancer agent by using nanotechnology.

Source link: https://doi.org/10.1007/s43450-022-00250-0


Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN)

The 9th web-based European Conference on Infections in Leukemia, held September 16-to- 2021, reviewed the risk of infections and febrile neutropenia with more recently approved immunotherapeutic agents and molecular targeted drugs for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. Although the majority of these agents are not associated with an elevated risk when used as monotherapy, a majority of these agents, venetoclax plus hypomethylating agents, gemtuzumab ozogamicin plus cytotoxic drugs, or midostaurin were not added to conventional AML chemotherapy.

Source link: https://doi.org/10.1038/s41375-022-01556-7


Incidence, risk factors, and management of bleeding in patients receiving anticoagulants for the treatment of cancer-associated thrombosis

According to a personalized strategy matched the right drug to the right patient, updated clinical practice guidelines recommend the long-term use of low-molecular-weight heparins or direct oral anticoagulants as the treatment of cancer-associated thrombosis. Bleeding complications have been reported to be more prevalent in cancer patients receiving anticoagulation therapy than in non-cancer patients, with a reported incidence of major bleeding ranging from 2. 4 to 16. 0% in randomized controlled trials. The aim of this article is to raise questions regarding bleeding disorders as a significant safety issue for CAT therapy, as well as analyzing results from new RCT and real-world studies to assist clinicians in decision-making.

Source link: https://doi.org/10.1007/s00520-021-06598-8


CRISPR/Cas9 and next generation sequencing in the personalized treatment of Cancer

Background Cancer is caused by a combination of genetic and epigenetic abnormalities. Personalized or precision medicine produces healthcare that is personalised to the individual and eliminates the limitations of “one-size-fits-all” therapy. NGS has been a major step in personalized medicine due to its ability over limited sample size and the recent introduction of biomarkers. Cancer treatment decisions are being aided by Tumor and cell-free DNA profiling using NGS, proteome, and RNA analysis, as well as a better understanding of immunological methods. With CRISPR/Cas9, it is also possible to precisely target tumor genes in cancer cells, allowing for elimination of genetic mutations that contribute to tumor formation and metastatic function. With NGS and CRISPR/Cas9, the aim is no longer to match the diagnosis of the illness or the diagnosed tumor, but rather to develop a treatment strategy that conforms the tumor exactly.

Source link: https://doi.org/10.1186/s12943-022-01565-1


Explaining chemical clues of metal organic framework-nanozyme nano-/micro-motors in targeted treatment of cancers: benchmarks and challenges

Consequently, the design and application of nano-/micro-motors based on metal-organic frameworks with nanozyme activity in biomedical research have piqued significant interest lately. This article explores how to make biocompatible nanomotors to investigate the advantages and drawbacks of the required propellants, as well as medical research since reducing the toxicity of MOF-NZ nano/micro-motors. It was also revealed that MOF-NZ nano-/micro-motors can be useful in cancer therapy by the potential synergy of nanomotors with different therapies. In addition to presenting new research to solve existing problems, we hope that by analyzing the potential risks of MOF-NZ nano-/micro-motors in the care of cancers, we may be able to inspire researchers to produce MOF-NZs-based nanomotors.

Source link: https://doi.org/10.1186/s12951-022-01375-z


One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost–benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ)

In solid cancer patients, antiresorptive drugs have become the backbone of medical support for bone metastases. In addition, news of the increased risk of osteonecrosis of the jaw in bone metastatic cancer patients receiving long-term antiresorptive drugs is likely to influence therapy selection in the real-life situation.

Source link: https://doi.org/10.1007/s00520-022-06982-y

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions